These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 38167329)

  • 21. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
    Zhang C; Zhuang Q; Liu J; Liu X
    ACS Synth Biol; 2022 Jan; 11(1):1-15. PubMed ID: 35005887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies.
    de Lima SCG; Fantacini DMC; Furtado IP; Rossetti R; Silveira RM; Covas DT; de Souza LEB
    Adv Exp Med Biol; 2023; 1429():85-110. PubMed ID: 37486518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward the clinical development of synthetic immunity to cancer.
    Garcia JM; Burnett CE; Roybal KT
    Immunol Rev; 2023 Nov; 320(1):83-99. PubMed ID: 37491719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein engineering: a driving force toward synthetic immunology.
    Cox JR; Blazeck J
    Trends Biotechnol; 2022 Apr; 40(4):509-521. PubMed ID: 34627648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic receptors to understand and control cellular functions.
    Chang HJ; Bonnet J
    Methods Enzymol; 2020; 633():143-167. PubMed ID: 32046843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unlocking the potential of Tregs: innovations in CAR technology.
    Requejo Cier CJ; Valentini N; Lamarche C
    Front Mol Biosci; 2023; 10():1267762. PubMed ID: 37900916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secretory co-factors in next-generation cellular therapies for cancer.
    Okuma A; Ishida Y; Kawara T; Hisada S; Araki S
    Front Immunol; 2022; 13():907022. PubMed ID: 36059449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors.
    Abken H
    Hum Gene Ther; 2021 Oct; 32(19-20):1011-1028. PubMed ID: 34405686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptors: driving immunology towards synthetic biology.
    Sadelain M
    Curr Opin Immunol; 2016 Aug; 41():68-76. PubMed ID: 27372731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells.
    Luo H; Wu X; Sun R; Su J; Wang Y; Dong Y; Shi B; Sun Y; Jiang H; Li Z
    Front Oncol; 2019; 9():1448. PubMed ID: 31921693
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Weinberg ZY; Soliman SS; Kim MS; Chen IP; Ott M; El-Samad H
    bioRxiv; 2024 Jan; ():. PubMed ID: 38293112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic Receptors for Sensing Soluble Molecules with Mammalian Cells.
    Scheller L
    Methods Mol Biol; 2021; 2312():15-33. PubMed ID: 34228282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
    Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
    Front Immunol; 2018; 9():2231. PubMed ID: 30364107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New CARs on and off the road: challenges and new developments in CAR-T cell therapy.
    Wehrli M; Maus MV
    Curr Opin Pharmacol; 2021 Aug; 59():116-126. PubMed ID: 34198161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric antigen receptors that trigger phagocytosis.
    Morrissey MA; Williamson AP; Steinbach AM; Roberts EW; Kern N; Headley MB; Vale RD
    Elife; 2018 Jun; 7():. PubMed ID: 29862966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands.
    Chang ZL; Hou AJ; Chen YY
    Nat Protoc; 2020 Apr; 15(4):1507-1524. PubMed ID: 32103205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intelligent cell-based therapies for cancer and autoimmune disorders.
    Chen R; Jing J; Siwko S; Huang Y; Zhou Y
    Curr Opin Biotechnol; 2020 Dec; 66():207-216. PubMed ID: 32956902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.